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Summary
Background: The nasal vaccine candidate (NASVAC), comprising hepatitis B virus (HBV) surface
(HBsAg) and core antigens (HBcAg), has been shown to be highly immunogenic in animal models.
Methods: A phase I double-blinded, placebo-controlled randomized clinical trial was carried out in
19 healthy male adults with no serologic markers of immunity/infection to HBV. This study was
aimed at exploring the safety and immunogenic profile of nasal co-administration of both HBV
recombinant antigens. The trial was performed according to Good Clinical Practice guidelines.
Participants ranged in age from 18 to 45 years and were randomly allocated to receive a mixture
of 50 mg HBsAg and 50 mg HBcAg or 0.9% physiologic saline solution, as a placebo, via nasal spray
in a five-dose schedule at 0, 7, 15, 30, and 60 days. A total volume of 0.5 ml was administered
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in two dosages of 125 ml per nostril. Adverse events were actively recorded 1 h, 6 h, 12 h, 24 h,
48 h, 72 h, 7 days and 30 days after each dose. Anti-HBs and anti-HBc titers were evaluated
using corresponding ELISA kits at days 30 and 90.
Results: The vaccine candidate was safe and well tolerated. Adverse reactions included sneezing
(34.1%), rhinorrhea (12.2%), nasal stuffiness (9.8%), palate itching (9.8%), headache (9.8%), and
general malaise (7.3%). These reactions were all self-limiting and mild in intensity. No severe or
unexpected events were recorded during the trial. The vaccine elicited anti-HBc seroconversion in
100% of subjects as early as day 30 of the immunization schedule, while a seroprotective anti-HBs
titer (10 IU/l) was at a maximum at day 90 (75%). All subjects in the placebo group remained
seronegative during the trial.
Conclusion: The HBsAg—HBcAg vaccine candidate was safe, well tolerated and immunogenic in
this phase I study in healthy adults. To our knowledge, this is the first demonstration of safety and
immunogenicity for a nasal vaccine candidate comprising HBV antigens.
# 2006 International Society for Infectious Diseases. Published by Elsevier Ltd. All rights reserved.Introduction
According to theWorld Health Organization, there weremore
than 400 million carriers of hepatitis B virus (HBV) worldwide
by the year 2000.1,2 Among these, approximately 5—10% of
adults and 80—90% of children became chronic carriers of the
virus. The long-term consequences of chronic carriage are
cirrhosis, liver failure and hepatocellular carcinoma.3,4 This
fact, along with the partial efficacy of antiviral therapies,
their cost and side effects, underlines the need for devel-
opment of more immunogenic hepatitis B vaccines.5 This kind
of vaccine could be used in specific active immunotherapy in
HBV chronically infected patients or chronic carriers.
An impaired T-cell immune response to major HBV anti-
gens is a common scenario in patients with chronic infection.
Conversely, patients resolving acute hepatitis, those with
chronic infection resolving spontaneously, and patients
who control the virus after treatment, display strong poly-
clonal and multi-specific helper and cytotoxic T-cell
responses against HBV nucleocapsid, polymerase and envel-
ope proteins.6—9
Chronic HBV infection has also been associated with func-
tional defects in dendritic cell populations (DC).10—12 Addi-
tionally, the secretion of HBeAg in saliva of the majority of
infected patients has been detected. The negative immuno-
modulatory effect of the secreted protein in suppressing an
inflammatory Th1 response vital for viral clearance has been
consistently demonstrated.13
Recent developments to boost the weak HBV-specific
immune response or to break the non-responsiveness of T-cell
immunity in chronic patients include combined prophylactic
vaccines, plant-derived vaccines, vaccines administered
through novel routes or with novel adjuvants, gene vaccine,
and peptide vaccine.5,14—24
The Center for Genetic Engineering & Biotechnology in
Havana has developed NASVAC, a novel hepatitis B vaccine
candidate for nasal administration comprising HBsAg and
HBcAg as vaccine antigens. NASVAC is based on the results
of preclinical studies that have demonstrated a good safety
and immunogenicity profile.25 Recent advances in the field of
devices and methodologies for mucosal immunization further
benefit this strategy.26
Nasal administration enables antigens to access very spe-
cialized mechanisms for antigen sampling, including antigen
uptake by M cells.27 M cells transport antigens from theluminal surface through a thin cytoplasm to a pocket at
the basal surface. M cell pockets enable the interaction of
the antigen with the cells of the immune system in a com-
partment protected from the modulatory effect of systemic
immunity. Nasal administration also allows interaction of the
antigens with DC in the tonsils, where professional antigen
presenting cells (APCs) are organized in a surface network of
approximately 500 DC/mm2.27
HBcAg has been demonstrated to be the immunodominant
antigen at the Th cell and cytotoxic T lymphocytes (CTL) level
in patients with self-limited HBV infection and might, there-
fore, be relevant for virus control.24,28—30 Recombinant
HBcAg can induce strong HBV core (HBc)-specific Th cell
and antibody responses in mice reconstituted with peripheral
blood mononuclear cells (PBMCs) from patients with chronic
HBV infection.31 In vaccine studies, HBcAg has been shown to
be a potent immunogen even without adjuvants.32,33
Preclinical studies in mice with the combined HBsAg and
HBcAg nasal vaccine candidate showed a high mucosal (nasal)
immunogenicity of full length HBcAg and the immunoenhan-
cing activity on co-administered HBsAg.25,34—36
The strong immunogenicity of HBcAg has been attributed
to its dual behavior as a T-cell dependent and independent
antigen. This is related to the ability of HBcAg to act as a
potent B-cell activator, enabling activated B cells to work
efficiently as primary APCs.37
Preclinical toxicological studies of the intranasal vaccine
candidate were undertaken to determine mucosal irritating
potential, acute toxicity, and local tolerance. All the experi-
ments conducted in Sprague—Dawley rats revealed neither
clinical adverse signs nor behavioural changes in animals
under the studied dose. These results indicated that
HBsAg—HBcAg vaccine candidate administered by intranasal
route was neither irritating nor induced local damage in the
nasal mucosa of the rats.38
In this work we studied the safety and preliminary immu-
nogenicity of nasal co-administration of HBcAg and HBsAg in a
phase I clinical trial in healthy adults.
Materials and methods
Vaccine
A single nasal vaccine formulation consisting of a mixture of
50 mg Pichia pastoris-derived recombinant HBsAg subtype
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ified recombinant full length HBcAg (CIGB, Havana, Cuba)
was used (Genbank accession number X02763). HBsAg was
produced as a 22 nm particle to more than 95% purity at the
CIGB production facilities as a component of the commercial
anti-HBV vaccine, Heberbiovac-HB1. The HBsAg antigen for
this vaccine only comprises the S protein, expressed and
purified as a non-glycosylated form. HBcAg was purified from
E. coli strain W3110, which had been transformed previously
with a plasmid containing the entire core antigen gene under
the control of a tryptophan promoter.35,36,39 The resulting
HBcAg had a purity superior to 95% and a size of 28 nm
as characterized by electron microscopy (EM) analysis.25
Further antigenicity studies were conducted to characterize
this particle.34 The vaccine candidate was diluted in sterile
phosphate buffer without any adjuvant. The mixture was a
sterile, aqueous and transparent liquid. Each vial contained
0.6 ml of the vaccine formulation. Sterile physiologic saline
solution at 0.9% was used as placebo. All study products
were stored in borosilicate 2R bulbs at 4 8C until use. Nasal
spray devices (Accuspray1, Becton-Dickinson) were filled on
the day of the inoculation under sterile conditions.
Study population
Subjects were healthy male adults between 18 and 45 years
of age. Volunteers were recruited into the study after obtain-
ing written informed consent. Individuals were eligible if
they had no history of hepatitis B infection or immunization
with hepatitis B vaccine, and were negative for HBsAg and
antibody tests against HBsAg and HBcAg. Individuals were
excluded from enrollment if they had clinically significant
acute or chronic diseases, immunosuppressive disorders or
medication, prior inoculation of any other nasal drug, beha-
vioral risk factors that might have resulted in recent exposure
to hepatitis B virus, treatment with blood products or immu-
noglobulin within 6 months of study entry, a history of
sensitivity to any component of the study vaccines, or had
abnormalities in blood screening regarding chemical and
basic hematology.
Study design, randomization, blinding and
immunization procedures
The study was designed as a single center, randomized pla-
cebo-controlled double-blinded study in 19 healthymale adult
volunteers. Written informed consent was obtained from all
participants prior to any study procedure; the study was
approved by the Research Ethics Board of the National Center
for Toxicology (CENATOX) and ‘‘Carlos J. Finlay’’ Hospital
(Havana, Cuba). All the participants were randomly allocated
in a ratio of 1:1 to vaccine or placebo group in a balanced
format using a computer-generated list of random numbers.
The vaccine was administered using a nasal spray device
(Accuspray1, Becton-Dickinson). Depending on the group to
which each subject was assigned, the volunteer received
either NASVAC or placebo delivered in a fixed volume of
125 ml in order to increase the residence time of the drug
over themucosa and to avoidanterior andposterior drippingof
the vaccine formulation in the nose or digestive tract. The
study nurse sprayed the formulation in each nostril with the
participant’s head tilted backwards which allowed expirationthrough themouth. Two applications per nostril were given 15
minutes apart. All subjects received a total dose of 0.5 ml.
Participants allocated to placebo received the same volume of
0.9% sterile saline solution. Although there was no possibility
that study staff or volunteers could detect differences
between vaccine formulation and placebo, study staff who
administered the vaccine were not involved in collection of
any clinical data. The recording of adverse events was made
actively, and always by a trained physician specializing in
internal medicine, toxicology or otorhinolaryngology. Neither
the study nurse who performed the inoculations at the time of
immunization, nor the physicians or volunteers were aware of
the vaccine allocation. All aspects of the trial were closely
assessed by a medical monitor from the sponsor institution.
Five doses of the vaccine were given via nasal spray at days 0,
7, 15, 30, and 60.
Clinical and serological monitoring
Participants were kept under observation at the hospital for
48 hours on administration of the first and the second vaccine
doses. Adverse events were actively recorded by study per-
sonnel before and 1 hour after each immunization for any
immediate adverse events as well as at 6 h, 12 h, 24 h, 48 h,
72 h, and 7 days post-immunization. The observation period
concluded at day 90 of the immunization schedule. Following
administration of the third vaccine dose the trial was carried
out on an outpatient basis but adverse events were mon-
itored over the same time intervals with the exception of the
observations at 6 h and 12 h post-immunization. Solicited
adverse events included anterior and posterior nasal drip-
ping, nasal stuffiness or congestion, sneezing, nasal itching,
palate itching, anosmia, nasal ulceration, and nasal bleed-
ing. Solicited systemic adverse events included fever, chills,
headache, muscle aches, decreased appetite, nausea, vomit-
ing, diarrhea, and cutaneous rash. Information on any other
symptoms, the use of non-steroid anti-inflammatory analge-
sics, non-planned medical consultations or doctor’s visits,
and hospitalizations were also collected and categorized by
body system. Adverse events were defined as absent, mild
(symptom present but not bothersome, a nuisance at most),
moderate (symptom bothersome, discomfort enough to
cause interference with usual activity, frequent and annoy-
ing, may require medical attention), or severe (symptoms
very distressing, interference with normal functioning, may
require medical attention). Serious adverse events were
defined as events that were fatal or life-threatening, that
caused a prolonged hospitalization, that resulted in a sig-
nificant, persistent, or permanent disability, or that required
intervention to prevent permanent impairment or damage. In
addition to self-reporting of nasal adverse reactions, a single
otorhinolaryngologist performed periodical examinations
with visualization of the nasal mucosa, septum and mucosal
blood vessel status after the administration of each dose of
the nasal vaccine. Furthermore, participants were instructed
to measure their axillary temperature and to recognize any
local or systemic adverse events.
Blood, saliva and nasal wash samples were collected at
baseline, 30 days and 90 days following the first inoculation.
Blood was obtained by venipuncture for measurement of
serum clinical chemistry and basic hematological para-
meters. The total serum antibody response to HBsAg and
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enzyme linked immunosorbent assay (anti-HBs/anti-HBc
UMELISA1, Immunoassay Center, Havana, Cuba).40,41
Briefly, anti-HBs UMELISA40 is an enzyme-linked immuno-
sorbent assay (ELISA) adapted to small volumes of samples
and reagents (10 ml), based on the principle of neutralization
using the same typical sandwich as in other commercial anti-
HBs ELISA kits. Samples are pre-incubated with natural HBsAg
(subtype adw2) obtained from serum of a chronic HBV
infected patient with high HBsAg titer. Anti-HBs in sera block
antigenic determinants on the HBsAg. Recombinant HBsAg
reacts with solid phasemonoclonal antibodies. The binding of
HBsAg is evidenced by the successive reaction of the con-
jugate anti-HBs—alkaline phosphatase and a fluorescent sub-
strate. The reduction of the fluorescent signal will be
proportional to the concentration of anti-HBs in the sample.
Anti-HBc UMELISA41 is a competitive sequential immu-
noenzymatic assay for qualitative detection of total anti-
HBc antibodies in human sera. Briefly, UMELISA plates (10 ml
per well) coated with commercial recombinant HBcAg (Bio-
kit, Barcelona, Spain) are incubated with samples. Solid
phase antigen will react with antibodies from serum. A rabbit
anti-HBc—alkaline phosphatase conjugate is added, reacting
with remaining determinants. After the addition of a fluori-
genic substrate, the intensity of the emitted fluorescence
will be inversely proportional to the anti-HBc in the sample.
All blood samples were evaluated in duplicate in a blinded
fashion on code-labeled, matched pre- and post-immuniza-
tion sera. Only anti-HBs antibodies were measured in saliva
and nasal wash samples. All anti-HBs antibody levels were
expressed as international units per liter (IU/l) according to
the World Health Organization standard. The criterion for
protection was defined as concentration of anti-HBs equal to
or higher than 10 IU/l. Thus, the subjects were classified as
non-responders (anti-HBs <10 IU/l), low-responders (anti-
HBs 10—100 IU/l), and high-responders (anti-HBs >100 IU/
l).42,43 Sera with undetectable anti-HBs antibody were
assigned arbitrarily a value of 0.2 IU/l for analysis.
Anti-HBc antibody was expressed as a positive or negative
result. On completion of the study, the recombinant Heber-
biovac HB1 (CIGB, Havana, Cuba) licensed hepatitis B vac-
cine was provided to participants who had not achieved
antibody levels 100 IU/l.
Data analysis and statistical considerations
Baseline comparability of the groups was assessed by Fisher’s
exact test for proportions and the t-test for continuous vari-
ables. Adverse events were tabulated by time (day) and by
severity (mild, moderate, and severe). Clinically significant
events were defined as an axillary temperature 38.0 8C and
any other symptom graded as moderate or severe. Severe
reactionswere defined as axillary temperature39 8Cand any
symptomgradedas severe.Local site reactionswerecombined
to give an ‘any local’ reaction category and all other reactions
combined to give an ‘any general’ reaction category. The
proportion of subjects having an adverse reaction was esti-
mated by treatment group, observation period, and severity.
Binomial distribution point estimates and 95% confidence
intervals were used to estimate each rate; percentages were
compared by Fisher’s exact test. A p value <0.05 was con-
sidered statistically significant; no adjustments weremade formultiple comparisons. Geometric mean anti-HBs antibody
levels and 95% confidence intervals were estimated pre- and
post-immunization.
The primary outcome of the study was the proportion of
subjects reporting specific post-inoculation adverse reac-
tions. The secondary outcomes were: the proportion of sub-
jects showing antibody levels against HBsAg 10 IU/l
(seroprotection percentage), anti-HBc seroconversion after
immunization, and the geometric mean anti-HBs antibody
level. As this was a phase I, first-in-human clinical trial, no
formal hypothesis testing was planned and no formal sample
size calculation was performed; however, each treatment
group sample size (nine participants as minimum) ensured
that the probability of detecting at least one adverse event in
the groupwas 0.73, provided that the true adverse event rate
exceeded 15%.
Results
Demographics
A total of 43 subjects signed a written informed consent and
underwent pre-study screening; reasons for ‘screen failures’
included persistently abnormal baseline biochemistry or
hematology tests (4), pre-existing antibody against hepatitis
B virus (anti-HBs or anti-HBc antibodies) (17), and inability to
contact after the screening visit (3). The remaining 19 parti-
cipants were randomized and received study drug. The mean
age of participants was 29.7 years (range 18—45 years). There
were no differences in the age, weight and height between
vaccine and placebo group. Individuals of white race pre-
dominated during the trial. Nine participants received the
nasal vaccine candidate and 10 the placebo solution. All but
two participants completed the study; one subject in the
vaccine group and one in the placebo group withdrew volun-
tarily from the study prior to the fourth immunization. With-
drawal from the trial was not related to any adverse event in
both cases.
Safety and clinical adverse events
Exposure to the nasal formulation was evaluated during a 90-
day period following administration of the first vaccine dose
at time 0. No abnormalities in clinical chemistries and hema-
tology values were found in participants during the study. A
total of 77 adverse events were recorded during 90 applied
doses (85.5%). More than 97% of adverse events were mild in
intensity and 98.7% of them were requested on the data
collection sheets. The 77 recorded adverse events were
reported by 15 participants of the 19 included in the statis-
tical analysis. There was no difference in the proportion of
subjects reporting adverse events between study and control
group. The reporting of adverse events within the first hour
after vaccine administration was infrequent. Adverse events
were mostly reported during the first and second dose and
between 24 h and 72 h following inoculation. The recording
of local adverse events predominated over systemic reac-
tions (71.4%). The vaccine group reported the highest fre-
quency of local adverse events (58.2%), whereas systemic
adverse effects predominated in the placebo group (59.1%).
The most commonly reported nasal adverse events in the
study group included sneezing (34.1%), rhinorrhea (12.2%),
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Table 1 Frequency of each type of adverse event with
respect to the total number of applied doses per study group
Adverse event/
group
Vaccine
candidate
Placebo Total
Total of applied
doses
42 48 90
Requested adverse events
Sneezing 14 (18.2%) 4 (5.2%) 18 (23.4%)
Rhinorrhea 5 (6.5%) 3 (3.9%) 8 (10.4%)
Nasal itching 1 (1.3%) 8 (10.4%) 9 (11.7%)
Nasal stuffiness 4 (5.2%) 2 (2.6%) 6 (7.8%)
Local pain 0 1 (1.3%) 1 (1.3%)
Epistaxis 2 (2.6%) 0 2 (2.6%)
Palate itching 4 (5.2%) 0 4 (5.2%)
Anosmia 0 2 (2.6%) 2 (2.6%)
Odynophagia 2 (2.6%) 2 (2.6%) 4 (5.2%)
Local edema 0 1 (1.3%) 1 (1.3%)
Headache 4 (5.2%) 4 (5.2%) 8 (10.4%)
Febricula 1 (1.3%) 2 (2.6%) 3 (3.9%)
Asthenia 0 5 (6.5%) 5 (6.5%)
General malaise 3 (3.9%) 2 (2.6%) 5 (6.5%)
Unsolicited adverse events
Vasovagal syncope 1 (1.3%) 0 1 (1.3%)
Total 41 (53.2%) 36 (46.8%) 77 (100%)
Source: data collection sheets.
Figure 1 Kinetics of the anti-HBsAg antibody response in
healthy adults nasally immunized with HBcAg—HBsAg vaccine
candidate. Vaccine schedule: 0, 7, 15, 30, and 60 days. Blood
samples were collected from subjects at days 30, 60, and 90.
Vertical arrows: nasal vaccine inoculations.nasal stuffiness (9.8%), palate itching (9.8%), headache
(9.8%), general malaise (7.3%), and epistaxis (4.9%). Only
the frequency of sneezing was significantly higher for the
vaccine recipients ( p = 0.0038). All reactions were self-limit-
ing, resolving within 72 h after inoculation, and were mild.
No development of mucosal alterations or transient nasal
conditions occurred during the study. No cases of fever were
registered. Only twomoderate adverse events were reported
during the trial corresponding to headache; both reports
came from the placebo group. No unexpected or severe
adverse event was recorded during the trial (Table 1).
Antibody response
At baseline, all participants were seronegative for anti-HBs
and anti-HBc antibodies (Table 2). No volunteers inoculated
with the placebo developed antibodies against HBsAg or
HBcAg. A total of two (25%) of the eight recipients of the
nasal vaccine candidate developed seroprotective antibody
titers against HBsAg and 100% showed seroconversion againstTable 2 Antibody response to HBcAg—HBsAg vaccine candidate i
HBcAg non-covalently linked to 50 mg HBsAg following the schedu
Group/time Vaccine candi
Day 0 D
N 9 8
Anti-HBcAg seroconversion % — 8
Anti-HBs seroprotection % (anti-HBs 10 IU/l) — 2
Source: data collection sheets.HBcAg at day 30 of the immunization schedule. In two
seroprotected vaccine recipients at day 30, one was con-
sidered a hyper-responder (>100 IU/l) and the other devel-
oped anti-HBs titers around 70 IU/l. One recipient of the
nasal vaccine and one from the placebo groupwithdrew from
the study prior to the fourth dose and serawere not available
for testing.
At day 90, 75% (6/8) of vaccine recipients achieved anti-
HBs protective levels (Figure 1). At this time 37.5% of ser-
oprotected subjects were considered hyper-responders and a
similar proportion hypo-responders. The geometric mean
antibody titer at this time was 64.8 IU/l. All the volunteers
in the study group remained positive for anti-HBc antibodies.
Thus, most of the participants needed a fourth or a fifth dose
to achieve protective anti-HBs antibody levels.
Discussion
The results of this phase I study indicate that the nasal
vaccine candidate formulated with 50 mg HBsAg mixed with
50 mg HBcAg was well tolerated, safe and immunogenic in
healthy adults. Local site adverse events were mild, self-
limiting, and disappeared within 72 hours following inocula-
tion. Adverse events did not increase in frequency with the
administration of successive vaccine doses. Local adverse
events were reported more frequently in participants inocu-
lated with the nasal vaccine candidate, whereas systemic
adverse events were more frequently reported among indi-
viduals of the placebo group. Sneezing, palate itching, rhi-
norrhea, nasal stuffiness and epistaxis were the most
frequent adverse events reported in the vaccine group, with
approximately 2.6—13% excess over the frequency in then healthy volunteers immunized by the nasal route with 50 mg
le 0, 7, 15, 30, and 60 days
date Placebo
ay 30 Day 90 Day 0 Day 30 Day 90
8 10 9 9
(100%) 8 (100%) — — —
(25%) 6 (75%) — — —
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of an adverse event. There were also no clinically apparent
abnormalities visualized in vaccine recipients according to
otorhinolaryngologist examination.
The rates of local adverse events in this study were similar
to those reported by other investigators with licensed nasal
flu vaccine using similar surveillance methods.44 Concurrent
comparison with other licensed nasal vaccine (e.g. influenza,
nasal flu) would be informative as this vaccine has an accep-
table local adverse event profile under routine use.
In this study, 100% of the participants inoculated with the
nasal vaccine candidate demonstrated seroconversion for
anti-HBc antibodies and 25% showed protective levels of
anti-HBs only 30 days after the first inoculation, using an
immunization interval protocol of 0, 7, 15, 30, and 60 days.
All sera were available for screening at day 30. Thirty days
after the fifth vaccine dose the seroprotection rate increased
to 75%. By comparison, licensed HBV is reported to elicit a
seroprotective response in up to 20% of healthy young adults
30 days after the first dose injection and up to 71% in
recipients one month after the second dose.45—47 In this
sense, although three doses were administered by day 30
to get 25% seroprotection, we consider our results to be very
encouraging taking into consideration that the formulation
and devices still need to be improved.
The dose of 50 mg of HBcAg was enough to elicit ser-
oconversion in 100% of vaccine recipients as early as the
third dose; however five vaccine doses were needed to
reach 75% seroprotection with respect to anti-HBs titers
of more than 10 IU/l. Although anti-HBc quantification was
not possible, the strong immunogenicity of this antigen is
clearly evident and corroborates previous findings in
experiments in mice with full-length recombinant HBcAg.
The strong mucosal immunogenicity is also likely to be
related to its particulate nature as has been reported
previously for other particulate antigens.48 The presence
of nucleic acids bound to the C-terminal region of the
HBcAg molecule, as revealed by EM analysis, could also
contribute to the strong immunogenicity of HBcAg. E. coli
nucleic acids are co-purified with recombinant HBcAg par-
ticles as a nucleoprotein in trace amounts.25
Similarly, we have confirmed the detection of a positive
response in a nasal wash and saliva from one hyper-responder
volunteer generating more than 10 IU/l in such samples. How-
ever, our methods for the detection of IgA should be improved
in terms of sensitivity. Similarly, further assays are required for
the detection of cellular responses against HBsAg and HBcAg,
considering the potential therapeutic use of the present for-
mulation. Phase II clinical studies should address this issue.
This study clearly demonstrates that nasal HBsAg—HBcAg
vaccine candidate was well tolerated and reasonably immu-
nogenic for the dose of HBsAg used and the stage of the trial
(phase I). However, further studies should address the impact
of HBcAg immunomodulation on HBsAg immunogenicity. Pre-
clinical mouse studies have fully demonstrated the immuno-
potentiating activity of HBcAg over nasally/parenteral
administered HBsAg in mice and rabbits, with induction of
a Th1 type of cytokine response in mice.25,34—36 The addition
of HBcAg to HBsAg significantly increases the rates of ser-
oprotection over that achieved by nasal immunization with
HBsAg alone or mixed with other mucosal adjuvant (e.g.
acemannan). Whether the enhancement observed in theanimal studies is relevant to the clinical situation should
be confirmed in further immunogenicity studies.
Despite the limitations explained above, the nasal vaccine
candidate tested was well tolerated and induced serum anti-
body responses against both antigens. Rates of adverse events
were not substantially different than those reported in reci-
pients of other nasal vaccines currently licensed by the Food
and Drug Administration in the USA (e.g. nasal-flu) or other
well-known nasally-administered drugs of protein nature
(e.g.Miacalcin1nasal spray, calcitonin-salmon,Novartis).44,49
Induction of immunity against HBcAg and HBsAg exploiting
the mucosal immune system could be an effective approach
in the enhancement of antiviral immunogenicity in popula-
tions known to be hypo- or non-responders to the standard
parenteral HBV vaccine, such as older individuals, renal
dialysis patients, and immune compromised hosts, or in
populations that are difficult to access.50—52 Furthermore,
local and systemic immunity elicited by the nasal route of
immunization could be useful to overcome the well-docu-
mented state of unresponsiveness characteristic of HBV
chronic infection and the carrier state.
The results of this phase I study support further phase II
studies with HBsAg—HBcAg combined formulations in healthy
adults in order to optimize the dose, schedule, formulation,
and device. Also, chronic HBV infected patients and carriers
of the virus, as well as hypo- and non-responders to licensed
hepatitis B vaccines should be studied. To our knowledge, this
is the first report in humans of the administration of HBV
antigens by nasal route, showing induction of immunity
against HBV infection.
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